| Dr Oliver Samir Youssef, MD | |
|
925 Clifton Ave, Suite 203, Clifton, NJ 07013-2724 | |
| (973) 773-9250 | |
| (973) 773-9525 |
| Full Name | Dr Oliver Samir Youssef |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 29 Years |
| Location | 925 Clifton Ave, Clifton, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801826219 | NPI | - | NPPES |
| 0037133 | Medicaid | NJ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207YX0905X | Otolaryngology - Otolaryngology/facial Plastic Surgery | 25MA06664700 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Clara Maass Medical Center | Belleville, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ear, Nose And Throat Center Of Nj | 8426946542 | 2 |
News Archive
New interim results of a phase 1-2 clinical trial published in The Lancet Infectious Diseases tested the safety and effectiveness of an adjuvanted recombinant protein vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) called CoV2 preS dTM.
Eisai Co., Ltd. will launch ETAK( Antimicrobial Wet Wipes (classified as miscellaneous goods) containing long-acting antimicrobial agent ETAK on August 29, 2019 at pharmacies and drugstores countrywide.
A new study at Los Alamos National Laboratory and in collaboration with Stanford Synchrotron Radiation Lightsource greatly improves scientists' understanding of the element actinium. The insights could support innovation in creating new classes of anticancer drugs.
The second of two studies on latrepirdine, recently published in Molecular Psychiatry, demonstrates new potential for the compound in the treatment of Alzheimer's disease, Parkinson's disease, sleep disorders, and other neurodegenerative conditions. An international team led by Mount Sinai School of Medicine scientists found that latrepiridine, known commercially as Dimebon, reduced the level of at least two neurodegeneration-related proteins in mice.
Lithera, Inc., a clinical stage pharmaceutical company focused on lifestyle and medical indications in aesthetic medicine and ophthalmology, announced today that the first patient has been treated with LIPO-202 (Salmeterol Xinafoate for Injection) in its 500-patient Phase 2b "RESET" trial.
› Verified 7 days ago
| Entity Name | Ear, Nose & Throat Center Of Nj |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821276478 PECOS PAC ID: 8426946542 Enrollment ID: O20040309000946 |
News Archive
New interim results of a phase 1-2 clinical trial published in The Lancet Infectious Diseases tested the safety and effectiveness of an adjuvanted recombinant protein vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) called CoV2 preS dTM.
Eisai Co., Ltd. will launch ETAK( Antimicrobial Wet Wipes (classified as miscellaneous goods) containing long-acting antimicrobial agent ETAK on August 29, 2019 at pharmacies and drugstores countrywide.
A new study at Los Alamos National Laboratory and in collaboration with Stanford Synchrotron Radiation Lightsource greatly improves scientists' understanding of the element actinium. The insights could support innovation in creating new classes of anticancer drugs.
The second of two studies on latrepirdine, recently published in Molecular Psychiatry, demonstrates new potential for the compound in the treatment of Alzheimer's disease, Parkinson's disease, sleep disorders, and other neurodegenerative conditions. An international team led by Mount Sinai School of Medicine scientists found that latrepiridine, known commercially as Dimebon, reduced the level of at least two neurodegeneration-related proteins in mice.
Lithera, Inc., a clinical stage pharmaceutical company focused on lifestyle and medical indications in aesthetic medicine and ophthalmology, announced today that the first patient has been treated with LIPO-202 (Salmeterol Xinafoate for Injection) in its 500-patient Phase 2b "RESET" trial.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Oliver Samir Youssef, MD 115 Franklin Ave, Nutley, NJ 07110-2924 Ph: (973) 773-9250 | Dr Oliver Samir Youssef, MD 925 Clifton Ave, Suite 203, Clifton, NJ 07013-2724 Ph: (973) 773-9250 |
News Archive
New interim results of a phase 1-2 clinical trial published in The Lancet Infectious Diseases tested the safety and effectiveness of an adjuvanted recombinant protein vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) called CoV2 preS dTM.
Eisai Co., Ltd. will launch ETAK( Antimicrobial Wet Wipes (classified as miscellaneous goods) containing long-acting antimicrobial agent ETAK on August 29, 2019 at pharmacies and drugstores countrywide.
A new study at Los Alamos National Laboratory and in collaboration with Stanford Synchrotron Radiation Lightsource greatly improves scientists' understanding of the element actinium. The insights could support innovation in creating new classes of anticancer drugs.
The second of two studies on latrepirdine, recently published in Molecular Psychiatry, demonstrates new potential for the compound in the treatment of Alzheimer's disease, Parkinson's disease, sleep disorders, and other neurodegenerative conditions. An international team led by Mount Sinai School of Medicine scientists found that latrepiridine, known commercially as Dimebon, reduced the level of at least two neurodegeneration-related proteins in mice.
Lithera, Inc., a clinical stage pharmaceutical company focused on lifestyle and medical indications in aesthetic medicine and ophthalmology, announced today that the first patient has been treated with LIPO-202 (Salmeterol Xinafoate for Injection) in its 500-patient Phase 2b "RESET" trial.
› Verified 7 days ago
Ahmad F Mahmoud, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 6 Brighton Rd Ste 104, Clifton, NJ 07012 Phone: 973-470-0282 | |
Dr. Philip Stanley Ledereich, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1033 Clifton Avenue, Suites 204 And 206, Clifton, NJ 07013 Phone: 973-470-8266 Fax: 973-470-8288 |